• If you are wondering whether Recursion Pharmaceuticals at around US$3.39 is a bargain or a value trap, this article breaks down what the current share price might be telling you.
• The stock has been volatile, with a 3.4% decline over the last week, a 9.0% gain over the last 30 days, and longer term returns of 19.3% year to date and 40.5% over the last year.
• Recent coverage has focused on Recursion's position in biotechnology and how investor sentiment responds to updates on its platform and partnerships. These updates can quickly shift expectations for future cash flows. These developments help set the backdrop for why the share price has moved while the underlying business story continues to evolve.
• On Simply Wall St's valuation checks, Recursion scores 2 out of 6, and you can see the breakdown of that score in the valuation analysis. Next, we will look at how different valuation methods interpret that result and then finish with a framework that can help you make even more sense of the numbers.

Recursion Pharmaceuticals scores just 2/6 on our valuation checks. See what other red flags we found in the full valuation breakdown.

Approach 1: Recursion Pharmaceuticals Discounted Cash Flow (DCF) Analysis

A Discounted Cash Flow, or DCF, model takes estimates of a company’s future cash flows and discounts them back to today, aiming to arrive at an intrinsic value per share based on those projections.

For Recursion Pharmaceuticals, the latest twelve month Free Cash Flow is a loss of about $387.8 million. Analysts and model estimates project Free Cash Flow moving from losses in the near term to positive territory later in the decade. By 2030, the DCF model used here expects Free Cash Flow of about $176 million, with annual figures between 2026 and 2035 based on a mix of analyst inputs and extrapolations by Simply Wall St.

Using a 2 Stage Free Cash Flow to Equity model, these cash flows are discounted back to today to give an estimated intrinsic value of about $8.70 per share. Compared with a recent share price around $3.39, this suggests the stock may be trading below this DCF-based estimate of intrinsic value.

Result: UNDERVALUED

Our Discounted Cash Flow (DCF) analysis suggests Recursion Pharmaceuticals is undervalued by 61.0%. Track this in your watchlist or portfolio, or discover 50 more high quality undervalued stocks.

Approach 2: Recursion Pharmaceuticals Price vs Sales

For companies that are still loss making, earnings based metrics like the P/E ratio are not very helpful, so investors often focus on revenue based measures such as the P/S ratio. This lets you compare what the market is paying for each dollar of sales, while still keeping growth expectations and risk in mind, because faster growing or higher risk businesses can trade at very different sales multiples.

Recursion Pharmaceuticals currently trades on a P/S ratio of about 24.0x. That sits above both the Biotechs industry average of roughly 11.0x and the peer group average of about 15.2x. Simply Wall St’s Fair Ratio is a proprietary estimate of what the P/S multiple could be given factors such as the company’s growth profile, profit margin, industry, market cap and risk, and for Recursion it is about 0.00x.

Because the Fair Ratio adjusts for these fundamentals rather than relying only on simple peer or industry comparisons, it can give a more tailored view of value. Comparing the Fair Ratio of about 0.00x with the current P/S of 24.0x suggests the shares are trading above this Fair Ratio based estimate.

Result: OVERVALUED

P/S ratios tell one story, but what if the real opportunity lies elsewhere? Start investing in legacies, not executives. Discover our 17 top founder-led companies.

Upgrade Your Decision Making: Choose your Recursion Pharmaceuticals Narrative

Earlier it was mentioned that there is an even better way to understand valuation, so Narratives are introduced here as a simple story you tell about Recursion Pharmaceuticals that links your view of its business to specific numbers for future revenue, earnings, margins and a fair value estimate.

On Simply Wall St's Community page, Narratives let you turn that story into a financial forecast, compare the fair value from your Narrative with the current share price, and then decide for yourself whether the gap between value and price is large enough to act on.

These Narratives update automatically as fresh information arrives, so when Recursion posts new trial data, signs a partnership or reports earnings, the forecast and fair value attached to each Narrative refresh to reflect the latest inputs.

For example, one Recursion Narrative currently implies a fair value close to US$1.97 per share with more cautious assumptions around growth and profitability. Another points to a fair value near US$11.00 per share with much stronger expectations for revenue growth and future margins, which shows how different investors can look at the same company and reach very different conclusions about what the stock is worth.

For Recursion Pharmaceuticals, however, we will make it really easy for you with previews of two leading Recursion Pharmaceuticals Narratives:

These sit at opposite ends of the spectrum, which is exactly what you want when you are testing your own view against what other investors are thinking.

Fair value: US$8.38 per share

Implied undervaluation: about 60% compared to the recent price of US$3.39

Revenue growth assumption: 94%

• Views Recursion as moving from a "science project" to a commercial TechBio company, supported by clinical data, partnership milestones and a cash runway reportedly extending through 2027.
• Highlights over US$500m of partner inflows and specific program updates such as REC-4881 for FAP and REC-617 in oncology as key proof points for the platform.
• Assumes a profitable business later in the decade with around 25% net margins, which feeds into the higher fair value estimate relative to today’s share price.

Fair value: US$1.97 per share

Implied overvaluation: about 72% compared to the recent price of US$3.39

Revenue growth assumption: 52.84%

• Focuses on insider selling and the past share price decline from above US$40 to under US$4 as key concerns about alignment between management and shareholders.
• Points out that previous expectations for a large number of drugs have not yet materialised, which feeds into skepticism about the long term commercial opportunity.
• Treats the current share price as too high relative to execution so far, which is why the fair value is set below the recent trading level.

Together, these narratives frame a wide fair value range, from around US$1.97 to US$8.38 per share, and show how the same data can lead to very different conclusions once you plug in your own assumptions about execution, partnerships and clinical outcomes.

If you want to see how other investors are quantifying their stories about Recursion and stress test your own thesis against them, See what the community is saying about Recursion Pharmaceuticals.

Do you think there's more to the story for Recursion Pharmaceuticals? Head over to our Community to see what others are saying!

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.